(AEAGX) Agenix Limited receives over $AUD 2 Million on sale of AGX 1009

HD
WC
PD
SN
SC
LA
CY
LP

TD

(AEAGX) Agenix Limited receives over $AUD 2 Million on sale of AGX 1009

294 words
11 August 2014
Ralph Wragg Australian Business News
AAPRAW
English
Copyright 2014 RWE AUSTRALIAN BUSINESS NEWS PTY LTD. All Rights Reserved.

Sydney - Monday - August 11 (RWE) - Agenix Limited (ASX: AGX) receives proceeds of more than
$AUD2 Million from its AGX-1009 China Asset sale to Cinkate Pharmaceuticals Melbourne, Australia.
8 August 2014: Agenix Limited advises that its wholly owned subsidiary in China has received RMB
11,741,864 ($AUD 2,056,729) being the proceeds due for the sale of its AGX-1009 China project to
Cinkate Pharmaceutical Intermediates Co Ltd (Cinkate).

Under the terms of the sale announced on 19 May 2011, Cinkate has taken over development of
AGX-1009, a tenofovir prodrug for HBV patented in China sold by Agenix following completion of
preclinical studies.
Four three-party cooperation agreements were also signed by Cinkate, Agenix and its Chinese
development partners: the Institute of Medicinal Biotechnology, the Institute of Pharmacology and
Toxicology of the Academy of Military Medical Sciences, the Institute of Radiation Medicine of the
Academy of Military Medical Sciences, and HongHui Meditech.
Agenix chairman and chief executive Nick Weston said "The proceeds from the sale of AGX- 1009
demonstrates our focus on strengthening our balance sheet and exiting all operations in China".

For more information please contact: Nicholas Weston Tel: +61 3 8616 0379 About Agenix Agenix listed
on the Australian Securities Exchange in 1987.
Today, Agenix's lead product candidate is ThromboView, a novel radio- labelled monoclonal antibody
imaging modality for pulmonary embolism (PE) and deep vein thrombosis (DVT).

Agenix's human health diagnostics platform, DiagnostlQ is a patented disposable point-of- care test
device with reader.

DiagnostlQ utilises an antibody/antigen printed membrane, a unique pre- filter device and an incubation
chamber in a flow-through format to create a sensitive and quantitative, rapid, test.

CO
IN

NS
RE

PUB
AN

btchi : Agenix Ltd
i257 : Pharmaceuticals | i951 : Health Care/Life Sciences | i372 : Medical Equipment/Supplies | iphmed :
Medical/Surgical Instruments/Apparatus/Devices
ccat : Corporate/Industrial News
china : China | austr : Australia | apacz : Asia Pacific | asiaz : Asia | ausnz : Australia/Oceania | bric :
BRIC Countries | chinaz : Greater China | devgcoz : Emerging Market Countries | dvpcoz : Developing
Economies | easiaz : Eastern Asia
RWE Australian Business News Pty Ltd
Document AAPRAW0020140810ea8b000jk

Page66of269Â©2018Factiva,Inc.Allrightsreserved.